Risultati per: La FDA approva il sistema di riabilitazione dell’ictus

New England Journal of Medicine, Ahead of Print.

This cross-sectional study determines the frequency of and rationale for US Food and Drug Administration (FDA) approval of drugs not meeting pivotal trial primary efficacy end points.

This cross-sectional study evaluates regulatory decisions and health technology assessments in Australia, Canada, and the UK regarding new drugs approved by the US Food and Drug Administration in 2017 through 2020, as well as estimates the US cost per patient per year for drugs receiving negative recommendations.

This cross-sectional study evaluates patient exposure to oncology drugs withdrawn from the US Food and Drug Administration (FDA) Accelerated Approval program.

Soc. italiana ictus, ‘urge omogeneità cura su tutto territorio’

Con la campagna didattica Fast Heroes di Alice Italia

In late February, the US Food and Drug Administration (FDA) granted an Emergency Use Authorization to an at-home diagnostic test that identifies SARS-CoV-2, the virus that causes COVID-19, as well as influenza strains A and B. The test detected 100% of negative and 88.3% of positive COVID-19 samples, 99.3% of negative and 90% of positive influenza A samples, and 99.9% of negative influenza B samples.

La campagna mondiale dal 13 al 19 marzo

New England Journal of Medicine, Ahead of Print.

Per gli adulti, agisce in 15 minuti su dolore e altri sintomi

The US Food and Drug Administration (FDA) has approved the first oral treatment for anemia caused by chronic kidney disease.

This study examines the Food and Drug Administration’s accelerated approval pathway and whether preapproval initiation was associated with faster conversion to traditional approval or withdrawal for drugs with nononcology indications.

La terapia cellulare per il trattamento del glioblastoma multiforme, tumore cerebrale molto aggressivo, rappresenta un cambio di paradigma nell’approccio a una malattia che a oggi non ha una cura

This quality improvement study identifies adverse events for inferior vena cava filters and reports changes in adverse event reporting and estimated insertions between 2016 and 2020 in the US.